A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Fizazi, Karim; Lesaunier, F.; Delva, R.; Gravis, Gwénaëlle; Rolland, Frédéric; Priou, Frank; Ferrero, Jean-­Marc; Houédé, Nadine; Mourey, Loïc; Théodore, Christine; Krakowski, I.; Berdah, Jean-François; Baciuchka, Marjorie; Laguerre, Brigitte; Fléchon, Aude; Ravaud, Alain; Cojean-Zelek, Isabelle; Oudard, Stéphane; Labourey, Jean-Luc; Lagrange, Jean‐Léon; Chinet-Charrot, P.; Linassier, Claude; Deplanque, Gaël; Beuzeboc, Philippe; Genève, Jean; Davin, Jean-Louis; Tournay, Elodie; Culine, Stéphane

doi:10.1016/j.ejca.2011.10.015

Cited by 49 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy in addition to RT for the treatment of localized PCa has been attempted in some clinical trials. In the GETUG 12 randomized trial conducted in men with high‐risk PCa , neoadjuvant docetaxel/estramustine plus ADT before local treatment (primarily RT) was associated with a higher PSA response rate and had a favourable safety profile compared to ADT alone, but the impacts on relapse and survival need to be further assessed. Adjuvant chemotherapy after RT has also been studied.…”

Section: Resultsmentioning

confidence: 99%

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

Poon

Chan

et al. 2019

BJU International

View full text Add to dashboard Cite

ObjectiveTo formulate consensus statements to facilitate physician management strategies for patients with clinically localized prostate cancer (PCa) in Hong Kong by jointly convening a panel of 12 experts from the two local professional organizations representing PCa specialists, who had previously established consensus statements on the management of metastatic PCa for the locality.MethodsThrough a series of meetings, the panellists discussed their clinical experience and the published evidence regarding various areas of the management of localized PCa, then drafted consensus statements. At the final meeting, each drafted statement was voted on by every panellist based on its practicability of recommendation in the locality.ResultsA total of 76 consensus statements were ultimately accepted and established by panel voting.ConclusionDerived from the recent evidence and major overseas guidelines, along with local clinical experience and practicability, the consensus statements were aimed to serve as a practical reference for physicians in Hong Kong for the management of localized PCa.

show abstract

Section: Resultsmentioning

confidence: 99%

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

Poon

Chan

et al. 2019

BJU International

View full text Add to dashboard Cite

show abstract

“…The D'Amico risk stratification system is widely utilized in the American Urologic Association and National Comprehensive Cancer Network guidelines, and is often used to determine eligibility for clinical trials [15,16]. Specifically, placement in the high-risk group is often a primary inclusion criterion of neoadjuvant clinical trials [17,18]. Publications have examined the differences in outcomes of D'Amico risk categories based on primary and secondary biopsy Gleason score (BGS) [19].…”

mentioning

confidence: 99%

Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score

et al. 2017

View full text Add to dashboard Cite

Aim: The aim of this study was to clarify and examine the outcomes of prostate cancer patients classified as intermediate risk (IR) using the D'Amico risk classification system, specifically focusing on the influence of primary and secondary biopsy Gleason score (BGS). Patients and Methods: An institutional review board-approved database of robotic-assisted radical prostatectomies performed after 2006 was stratified by standard D'Amico criteria. IR patients were then sub-stratified by BGS. Pathologic and intermediate-term biochemical disease-free survival (BDFS) outcomes were analyzed. Results: Overall, 1,090 patients were classified as D'Amico low-risk, 896 as IR, and 240 as high-risk. Of the 896 IR patients, 63 had BGS 6, 630 were 3 + 4 = 7, and 203 4 + 3 = 7. Among IR patients, as the BGS increased, there was an increasing likelihood of extracapsular extension (21, 28, and 38%, respectively; p = 0.005), positive surgical margins (14, 26, 31%; p = 0.048), and worse 3-year BDFS (96, 94, 88%; p = 0.01). Multivariable logistic regression and Cox regression analyses confirmed differences among IR groups. Conclusion: D'Amico IR patients demonstrate significant heterogeneity in both pathologic outcomes and BDFS. IR patients with a BGS of 6 appear to have similar intermediate-term BDFS as low-risk patients. An increasing BGS from 3 + 3 to 3 + 4 to 4 + 3 results in a higher likelihood of locally-advanced disease and intermediate-term biochemical failure.

show abstract

“…The median time to PSA progression was significantly increased to 30 weeks in arm B compared with 20 weeks in arm A (48). Subsequent studies of the impact of the combination of docetaxel-based chemotherapy with EMP on the quality of life showed significant decrease in pain with fewer symptoms in patients with CRPCs who were more likely to achieve a biochemical response (49,50). Overall, however, the side effects of estramustine continue to limit its routine use in the United States.…”

Section: Effects Of Estrogen Therapy On Microtubules In Prostate Cancermentioning

confidence: 99%

New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer

Mistry

2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Metastatic prostate cancer has limited therapeutic options and has remained a major clinical challenge. Historically, prostate cancer has been widely recognized as a chemotherapy-resistant disease. However, clinical studies with anti-microtubule agents over the past decade have shown important efficacy in improving survival in patients with advanced disease. The favorable outcomes with microtubule-targeted agents have thus rekindled interest in such therapies for the clinical management of prostate cancer. Microtubules are dynamic polymers of tubulin molecules that play diverse roles within the cell. The dynamic property of microtubules is responsible for forming the bipolar mitotic apparatus, the mitotic spindle, that functions to precisely segregate the chromosomes during cell division. Thus, owing to the pivotal role that they play in the orchestration of mitotic events, microtubules provide excellent targets for anti-cancer therapy. Recent evidence also suggests that microtubules play a crucial role in the regulation of endocrine signaling pathways. Interestingly, microtubule-targeted agents such as taxanes not only inhibit cell division but also impair endocrine receptor signaling in prostate cancer. Herein, we provide an overview of the current status of microtubule-targeted therapies that are used in the treatment of prostate cancer and discuss novel mechanisms by which such therapies modulate endocrine signaling in prostate cancer. We also address the emerging roles of microtubule regulatory proteins in prostate carcinogenesis that could serve as attractive targets for prostate cancer therapy and might also serve as predictive biomarkers to identify patients who may benefit from endocrine and/or chemotherapy. This may have important implications in designing mechanism-based and targeted-therapeutic strategies for prostate cancer. Mol Cancer Ther; 12(5); 555-66. Ó2013 AACR.

show abstract

A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Cited by 49 publications

References 41 publications

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score

New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer

Contact Info

Product

Resources

About